Aclaris Therapeutics, Inc. Appoints Kevin Scott as Vice President of Sales

MALVERN, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that it has appointed Kevin Scott, an experienced sales executive within the field of dermatology, as Vice President of Sales.

Mr. Scott brings more than 20 years of pharmaceutical commercialization experience to Aclaris. He has substantial experience with specialty dermatology companies and has successfully led sales, sales training, operations, and managed markets teams.

“Kevin is an excellent addition to the team as we continue to build Aclaris into a fully integrated specialty dermatology company. His extensive experience in building and leading sales teams will be invaluable as we develop our commercial organization,” said Brett Fair, Senior Vice President of Commercial Operations for Aclaris.

Mr. Scott joins Aclaris from Novartis Pharmaceuticals where he served as the Northeast Regional Sales Director. Prior to Novartis Pharmaceuticals, Mr. Scott served as Director of Sales for Taro Pharmaceuticals. He started his career at Dermik Laboratories where he held positions of increasing responsibility in sales and operations. Mr. Scott earned a Bachelor of Science degree from Johnson C. Smith University.

About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania and more information can be found by visiting the company’s website at www.aclaristx.com.

Contact: Aclaris Contact Neal Walker President and Chief Executive Officer 484-324-7933 info@aclaristx.com Investor Contact Patricia L. Bank Westwicke Partners Managing Director 415-513-1284 patti.bank@westwicke.com Media Contact Mike Beyer Sam Brown, Inc. 312-961-2502 mikebeyer@sambrown.com

Source:Aclaris Therapeutics, Inc.